

CITATION REPORT

List of articles citing

2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection

DOI: 10.1111/ajt.13909

American Journal of Transplantation, 2016, 16, 2816-2835.

Source: <https://exaly.com/paper-pdf/63359233/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
380	Antibody-Mediated Injury to the Transplanted Liver: Receiving the SagesPWisdom. <i>American Journal of Transplantation</i> , 2016 , 16, 2773-2774	8.7	1
379	Late graft hepatitis and fibrosis in pediatric liver allograft recipients: Current concepts and future developments. <i>Liver Transplantation</i> , 2016 , 22, 1593-1602	4.5	76
378	Acute antibody-mediated rejection in the liver allograft: A masquerade or new disease?. 2017 , 21, e12869		
377	Antibody-mediated rejection in the cardiac allograft: diagnosis, treatment and future considerations. 2017 , 32, 326-335		3
376	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. <i>Transplantation</i> , 2017 , 101, S1-S56	1.8	141
375	Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR ScoreB Ability to Determine Long-term Outcome. <i>Transplantation</i> , 2017 , 101, 2062-2070	1.8	10
374	Antibody-Mediated Rejection After Liver Transplant. 2017 , 46, 297-309		16
373	Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society. 2017 , 141, 437-444		35
372	Impact of transplant accessibility for sensitized patients by avoiding unacceptable antigens. <i>Liver Transplantation</i> , 2017 , 23, 880-886	4.5	2
371	Long-term outcomes of de novo autoimmune hepatitis in pediatric liver transplant recipients. 2017 , 21, e12945		17
370	Management of Immunosuppression in Liver Transplantation. 2017 , 21, 337-353		14
369	Optimal dosage regimen for rituximab in ABO-incompatible living donor liver transplantation. 2017 , 24, 89-94		16
368	Systematic review: recurrent autoimmune liver diseases after liver transplantation. 2017 , 45, 485-500		71
367	The First Six Months Following Liver Transplantation. 2017 , 1079-1092		
366	Longterm outcome of the liver graft: The pathologistB perspective. <i>Liver Transplantation</i> , 2017 , 23, S70-S75		6
365	Pathology primer: Common liver biopsy findings in patients who have recently undergone liver transplant or resection. 2017 , 10, 42-48		
364	Application and interpretation of histocompatibility data in liver transplantation. 2017 , 22, 499-504		6

363	Liver transplantation: Rejection and tolerance. <i>Liver Transplantation</i> , 2017 , 23, S85-S88	4.5	19
362	Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation. 2017 , 45, 8-14		17
361	Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know. <i>Journal of Clinical and Experimental Hepatology</i> , 2017 , 7, 358-366	4.1	53
360	Recurrent Disease Following Liver Transplantation. 2017 , 1127-1142		
359	Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. <i>Transplantation</i> , 2017 , 101, 2399-2409	1.8	29
358	Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation. 2017 , 32, 887-893		12
357	De novo autoimmune hepatitis after liver transplantation: A focus on glutathione S-transferase theta 1. <i>Liver Transplantation</i> , 2017 , 23, 75-85	4.5	7
356	The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. <i>American Journal of Transplantation</i> , 2017 , 17, 42-53	8.7	35
355	Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature. 2017 , 21, e12791		28
354	Immunosuppression: The Global Picture. 2017 , 1065-1078		
353	The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives. 2017 , 2017, 3234906		13
352	Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection. 2017 , 2017, 7903471		28
351	Severe Unresolved Cholestasis Due to Unknown Etiology Leading to Early Allograft Failure Within the First 3 Months of Liver Transplantation. <i>Transplantation</i> , 2018 , 102, 1307-1315	1.8	3
350	Isolated vascular "v" lesions in liver allografts: How to approach this unusual finding. <i>American Journal of Transplantation</i> , 2018 , 18, 1534-1543	8.7	4
349	HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection. 2018 , 200, 2372-2390		24
348	Histopathology of 460 liver allografts removed at retransplantation: A shift in disease patterns over 27 years. 2018 , 32, e13227		11
347	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , 2018 , 102, 727-743	1.8	84
346	Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. 2018 , 31, 649-657		6

345	Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation. <i>Liver Transplantation</i> , 2018 , 24, 1091-1100	4.5	26
344	Immunosuppression. 2018 , 431-444		
343	Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. 2018 , 40, 401-410		7
342	Long-term Outcomes of ABO-incompatible Pediatric Living Donor Liver Transplantation. <i>Transplantation</i> , 2018 , 102, 1702-1709	1.8	25
341	Obliterative portal venopathy: A histopathologic finding associated with chronic antibody-mediated rejection in pediatric liver allografts. 2018 , 22, e13124		7
340	Global quality assessment of liver allograft C4d staining during acute antibody-mediated rejection in formalin-fixed, paraffin-embedded tissue. <i>Human Pathology</i> , 2018 , 73, 144-155	3.7	7
339	Identification of the cellular components involved in de novo immune hepatitis: a quantitative immunohistochemical analysis. 2018 , 16, 62		3
338	Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. 2018 , 69, 626-634		25
337	Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients. <i>Liver Transplantation</i> , 2018 , 24, 897-907	4.5	15
336	De Novo Autoimmune Hepatitis After Living Donor Liver Transplantation: A Series of 4 Cases. <i>Journal of Clinical and Experimental Hepatology</i> , 2018 , 8, 314-317	4.1	
335	Successful living donor liver retransplantation for graft failure within 7 days due to acute de novo donor-specific anti-human leukocyte antigen antibody-mediated rejection. 2018 , 48, E360-E366		5
334	Long-term outcome of liver transplantation in childhood: A study of 20-year survivors. <i>American Journal of Transplantation</i> , 2018 , 18, 1680-1689	8.7	42
333	Regulatory dendritic cells for promotion of liver transplant operational tolerance: Rationale for a clinical trial and accompanying mechanistic studies. 2018 , 79, 314-321		38
332	Development of CD3 cell quantitation algorithms for renal allograft biopsy rejection assessment utilizing open source image analysis software. 2018 , 472, 259-269		10
331	Donor Specific Antibody Negative Antibody-Mediated Rejection after ABO Incompatible Liver Transplantation. 2018 , 32, 108		
330	De novo autoimmune hepatitis -is this different in adults compared to children?. 2018 , 95, 26-33		24
329	Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants. 2018 , 155, 1838-1851.e7		72
328	Decreased Incidence of Acute Cellular Rejection in Low-Muscle-Mass Recipients After Living-donor Liver Transplantation. 2018 , 50, 3626-3634		7

327	Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real-world cohort. 2018 , 32, e13411	5
326	Liver transplant pathology: a timeline based approach and review. 2018 , 24, 508-513	1
325	Transplantation Pathology. 2018 , 880-965	2
324	Tacrolimus and Single Intraoperative High-dose of Anti-T-lymphocyte Globulins Versus Tacrolimus Monotherapy in Adult Liver Transplantation: One-year Results of an Investigator-driven Randomized Controlled Trial. 2018 , 268, 776-783	6
323	Antibody-Mediated Rejection of Solid-Organ Allografts. 2018 , 379, 1150-1160	177
322	Histological findings in protocol biopsies following pediatric liver transplant: Low incidence of abnormalities at 5 years. 2018 , 22, e13212	7
321	Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies. 2018 , 92 Suppl 2, 34-37	6
320	Donor-Specific AntibodiesPMeaningful Impact on Liver Transplantation. <i>Liver Transplantation</i> , 2018 , 24, 999-1000	4-5
319	Acute, Chronic, and Humoral Rejection: Pathologic Features Under Current Immunosuppressive Regimes. 2018 , 11, 431-452	9
318	Clinical association of anti-glutathione S-transferase T1 antibodies and de novo immune hepatitis after hematopoietic cell transplantation. 2018 , 50, 418-419	2
317	Inflammasome Priming Mediated Toll-Like Receptors 2 and 4, Induces Th1-Like Regulatory T Cells in Autoimmune Hepatitis. 2018 , 9, 1612	12
316	Biopsy of the Liver. 2018 , 39-52	
315	Aktuelle Aspekte der Immunsuppression nach Transplantation solider Organe. 2019 , 14, 289-295	
314	Tablet or capsule form of generic mycophenolate mofetil (My-Rept) after liver transplantation: a prospective randomized trial. 2019 , 13, 2187-2193	
313	Donor-specific antibodies following liver and intestinal transplantation: Clinical significance, pathogenesis and recommendations. 2019 , 38, 106-117	8
312	Aktuelle Aspekte der Immunsuppression nach Transplantation solider Organe. 2019 , 22, 272-277	
311	Analysis of rabbit anti-thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients. 2019 , 23, e13573	2
310	Langzeitkomplikationen nach viszeraler Organtransplantation. 2019 , 14, 296-300	1

309	Endovascular stent placement for venous complications following pediatric liver transplantation: outcomes and indications. 2019 , 35, 1185-1195	15
308	The Role of Major Histocompatibility Complex in Organ Transplantation- Donor Specific Anti-Major Histocompatibility Complex Antibodies Analysis Goes to the Next Stage. 2019 , 20,	13
307	CT of acute rejection after liver transplantation: a matched case-control study. 2019 , 29, 3736-3745	4
306	Clinicopathologic characteristics of de novo nodular regenerative hyperplasia in pediatric liver transplant. 2019 , 23, e13471	2
305	Graft Immunocomplex Capture Fluorescence Analysis Can Detect Intragraft Anti-Major Histocompatibility Complex Antibodies in Mice Cardiac Transplant. 2019 , 51, 1531-1535	1
304	Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation. 2019 , 20, 605-612	8
303	Recurrent Idiopathic Liver Allograft Failure. 2019 , 152, 369-376	2
302	Immunosuppression in Pediatric Liver Transplant. 2019 , 555-564	1
301	Grading (and Classification) Systems Quick Reference: Solid Tumors. 2019 , 93-111	
300	Clearance of Intra-graft Donor Specific Anti-HLA Antibodies in the Early Stage of Antibody-Mediated Rejection Following Rituximab and Apheresis Therapy in Renal Transplantation. 2019 , 51, 1365-1370	2
299	Diagnostic Biomarkers to Diagnose Acute Allograft Rejection After Liver Transplantation: Systematic Review and Meta-Analysis of Diagnostic Accuracy Studies. 2019 , 10, 758	10
298	Preformed donor-specific antibodies are associated with 90-day mortality in living-donor liver transplantation. 2019 , 49, 929-941	6
297	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. 2019 , 96, 189-201	72
296	Prevalence and Impact of Reformed and De Novo Anti-HLA Donor-Specific Antibodies in Liver Transplantation. 2019 , 51, 424-428	3
295	Germinal Center Alloantibody Responses Mediate Progression of Chronic Allograft Injury. 2018 , 9, 3038	18
294	Liver Biopsy. 2019 , 395-407	
293	Low Titers of Antidonator ABO Antibodies After ABO-Incompatible Living Donor Liver Transplantation: A Long-Term Follow-Up Study. <i>Transplantation Direct</i> , 2019 , 5, e420	2.3 1
292	Exploring pre-surgery donor-specific antibodies in the context of organ shortage in liver transplant. 2019 , 404, 865-874	

291	Clinical Significance of Alloantibodies in Hand Transplantation: A Multicenter Study. <i>Transplantation</i> , 2019 , 103, 2173-2182	1.8	10
290	Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring. <i>Transplantation</i> , 2019 , 103, 1306-1322	1.8	16
289	Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase?. <i>Transplantation Direct</i> , 2019 , 5, e491	2.3	7
288	Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation. <i>Transplantation</i> , 2019 , 103, 1763-1775	1.8	19
287	It takes a village: primary care of the pediatric liver transplant recipient. 2019 , 31, 636-644		5
286	Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. <i>Hepatology</i> , 2019 , 69, 1273-1286	11.2	36
285	Age and liver transplantation. 2019 , 70, 745-758		73
284	The Role of Complement in Liver Injury, Regeneration, and Transplantation. <i>Hepatology</i> , 2019 , 70, 725-736	6.2	50
283	ABO-incompatible liver transplantation for children under 2 years of age: A case report and a single-center review. 2019 , 23, e13308		5
282	Recurrent and De Novo Autoimmune Hepatitis. <i>Liver Transplantation</i> , 2019 , 25, 152-166	4.5	37
281	Medical liver biopsy: background, indications, procedure and histopathology. 2020 , 11, 40-47		24
280	Outcome of Liver Transplant Patients With Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies. <i>Liver Transplantation</i> , 2020 , 26, 256-267	4.5	10
279	Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation. 2020 , 68, 142-149		5
278	Pathology of liver disease: advances in the last 50 years. <i>Human Pathology</i> , 2020 , 95, 78-98	3.7	5
277	Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy. 2020 , 24, e13611		2
276	Peripheral Donor-specific Antibodies Are Associated With Histology and Cellular Subtypes in Protocol Liver Biopsies of Pediatric Recipients. <i>Transplantation</i> , 2020 , 104, 1633-1643	1.8	9
275	Clinicopathological features and outcomes of parenchymal rejection in liver transplant biopsies. 2020 , 76, 822-831		2
274	Evaluation of a change in cytomegalovirus prevention strategy following pediatric solid organ transplantation. <i>Transplant Infectious Disease</i> , 2020 , 22, e13232	2.7	1

273	DSA Are Associated With More Graft Injury, More Fibrosis, and Upregulation of Rejection-associated Transcripts in Subclinical Rejection. <i>Transplantation</i> , 2020 , 104, 551-561	1.8	14
272	Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation. <i>Transplantation</i> , 2020 , 104, 1429-1436	1.8	4
271	Endothelial Cell-Derived Interleukin-18 Released During Ischemia Reperfusion Injury Selectively Expands T Peripheral Helper Cells to Promote Alloantibody Production. 2020 , 141, 464-478		12
270	Immunostaining Patterns of Posttransplant Liver Biopsies Using 2 Anti-C4d Antibodies. 2020 , 28, 146-153		3
269	Number of Antibody-verified Eplet in HLA-C Locus as an Independent Factor of T-cell-Mediated Rejection After Liver Transplantation. <i>Transplantation</i> , 2020 , 104, 562-567	1.8	5
268	Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients. 2020 , 40, 931-946		3
267	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020 , 72, 671-722	11.2	198
266	Single-Center North American Experience of Liver Transplantation in Autoimmune Hepatitis: Infrequent Indication but Good Outcomes for Patients. 2021 , 4, 137-144		2
265	Recipient risk factors for acute cellular rejection after orthotopic liver transplant - a single-center, retrospective study. 2020 , 33, 1779-1787		1
264	De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study. 2020 , 33, 1799-1806		0
263	De novo and recurrent liver disease. 2020 , 46-47, 101688		0
262	The Immunological Basis of Liver Allograft Rejection. 2020 , 11, 2155		23
261	Delta-like Canonical Notch Ligand 1 in Patients Following Liver Transplantation-A Secondary Analysis of a Prospective Cohort Study. 2020 , 10,		1
260	Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. 2020 , 5, 2202-2211		1
259	[Autoimmune liver diseases]. 2020 , 41, 444-456		
258	Successful management to prevent early graft loss due to Seventh-day Syndrome after liver retransplantation: A case report and literature review. 2021 , 25, e13907		0
257	[Liver transplantation. Current aspects of pretransplantation diagnosis and rejection]. 2020 , 41, 505-514		2
256	Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. 2020 , 10, 14242		9

255	Effect of on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients. 2020 , 9,		1
254	Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation. 2020 , 9,		1
253	Donor Specific Antibody and Long-Term Outcome After Liver Transplantation: A Systematic Review and Meta-Analysis. 2020 , 11, 613128		3
252	Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation. <i>American Journal of Transplantation</i> , 2020 , 20, 2173-2183	8.7	17
251	Late T cell-mediated rejection may contribute to poor outcomes in adolescents and young adults with liver transplantation. 2020 , 24, e13708		0
250	Glutathione S-Transferase T1 Mismatch Is a Risk Factor for Chronic Ductopenic Rejection of Liver Allografts. <i>Liver Transplantation</i> , 2020 , 26, 1287-1297	4.5	1
249	Adult liver transplantation: UK clinical guideline - part 2: surgery and post-operation. 2020 , 11, 385-396		5
248	Genomics and Liver Transplantation: Genomic Biomarkers for the Diagnosis of Acute Cellular Rejection. <i>Liver Transplantation</i> , 2020 , 26, 1337-1350	4.5	5
247	Living donor liver transplantation for congenital hepatic fibrosis in children. 2020 , 70, 348-354		2
246	Hepatitis E Is a Rare Finding in Liver Transplant Patients With Chronic Elevated Liver Enzymes and Biopsy-Proven Acute Rejection. 2020 , 52, 926-931		4
245	Autoimmune Hepatitis: Highlights for Liver Transplant Providers From the American Association for the Study of Liver Diseases 2019 Guidelines. <i>Liver Transplantation</i> , 2020 , 26, 973-976	4.5	1
244	The Human Immune Response to Cadaveric and Living Donor Liver Allografts. 2020 , 11, 1227		8
243	Pediatric Living Donor Liver Transplant in Indonesia's National Referral Hospital. <i>Transplantation</i> , 2020 , 104, 1305-1307	1.8	1
242	MicroRNAs 155-5p, 122-5p, and 181a-5p Identify Patients With Graft Dysfunction Due to T Cell-Mediated Rejection After Liver Transplantation. <i>Liver Transplantation</i> , 2020 , 26, 1275-1286	4.5	4
241	The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study. <i>American Journal of Transplantation</i> , 2020 , 20, 2156-2172	8.7	10
240	Donor-Specific Antibodies in Liver Transplantation. 2020 , 15, 13-16		4
239	Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study. 2020 , 59, 101272		4
238	Recurrent Disease After Liver Transplantation. 2020 , 19, 54-62		3

237	Donor-specific antibodies in liver transplantation. 2020 , 43, 34-45		
236	Donor-specific antibodies in liver transplantation. 2020 , 43, 34-45		9
235	Etiology of liver dysfunction after liver transplantation in children with metabolic disorders. 2020 , 50, 635-642		0
234	The role of complement activation in autoimmune liver disease. 2020 , 19, 102534		9
233	Do Recipients of Genetically Related Donors Have Better Outcomes After Living Donor Liver Transplantation?. <i>Journal of Clinical and Experimental Hepatology</i> , 2020 , 10, 334-338	4.1	1
232	Beyond 10 years, with or without an intestinal graft: Present and future?. <i>American Journal of Transplantation</i> , 2020 , 20, 2802-2812	8.7	5
231	A case of acute liver failure due to hepatitis E virus, liver transplantation, and development of de novo autoimmune hepatitis. <i>Transplant Infectious Disease</i> , 2020 , 22, e13287	2.7	2
230	Identification of HO-1 as a novel biomarker for graft acute cellular rejection and prognosis prediction after liver transplantation. 2020 , 8, 221		5
229	Outcome for Pediatric Recipients of Macrosteatotic Liver Grafts From Living Donors. <i>Liver Transplantation</i> , 2020 , 26, 899-905	4.5	
228	The histologic presentation of hepatitis E reflects patients' immune status and pre-existing liver condition. 2021 , 34, 233-248		4
227	Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft. 2021 , 155, 435-445		1
226	Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management. <i>Hepatology</i> , 2021 , 73, 1985-2004	11.2	14
225	The Liver in Organ Transplantation. 2021 , 380-409		
224	Approaches to Research Determination of Late Acute Cellular Rejection in Pediatric Liver Transplant Recipients. <i>Liver Transplantation</i> , 2021 , 27, 106-115	4.5	0
223	Donor-dominant one-way matching of human leukocyte antigen-A/B/DR alleles predicts graft-versus-host disease following living donor liver transplantation. 2021 , 51, 135-148		1
222	The real incidence of biliary tract complications after adult liver transplantation: the role of the prospective routine use of cholangiography during post-transplant follow-up. 2021 , 34, 245-258		1
221	Incidence of de novo autoimmune hepatitis in children and adolescents with increased autoantibodies after liver transplantation: a meta-analysis. 2021 , 34, 412-422		
220	Advances in Rejection Management: Prevention and Treatment. 2021 , 25, 53-72		0

219	HLA matching and rabbit antithymocyte globulin as induction therapy to avoid multiple forms of rejection after a third liver transplantation. 2021 , 45, 101539		1
218	Clinicopathologic Characteristics of Centrilobular Injury in Pediatric Liver Transplantation. <i>Liver Transplantation</i> , 2021 , 27, 416-424	4.5	1
217	Salivary inflammatory cytokines echo the low inflammatory burden in liver-transplanted children. 2021 , 25, 2993-2998		4
216	Immunological and Other Late Complications. 2021 , 255-264		
215	Long-Term Results of Liver Transplantation for Biliary Atresia. 2021 , 277-288		
214	Commentary: Late Allograft Fibrosis and Inflammation - An Unexpected Finding with Need for More Aggressive Treatment?. <i>Transplantation</i> , 2021 ,	1.8	
213	Evolving significance of liver pathology. 2021 , 64, S4-S5		
212	Knowledge, Attitude and Practices towards Hepatitis B Infection and Vaccination among Public Health Students in Ghana. 2021 , 11, 43-53		
211	Chronic Graft Injury. 2021 , 431-441		
210	Transplant and Autoimmune Diseases. 2021 , 281-293		
209	ABO Incompatibility: Indications and Management. 2021 , 70-78		
208	Liver Pathology. 2021 , 717-732.e3		
207	Role of Histology Following Pediatric Liver Transplantation. 2021 , 223-232		1
206	Types of Rejection. 2021 , 139-156		
205	Strategies for Liver Transplantation Tolerance. 2021 , 22,		3
204	Donor-Specific and Auto-Antibodies in Pediatric Liver Transplant: When Are They Important? What Do They Mean?. 2021 , 72, 643-644		
203	Short-term therapy with anti-ICAM-1 monoclonal antibody induced long-term liver allograft survival in nonhuman primates. <i>American Journal of Transplantation</i> , 2021 , 21, 2978-2991	8.7	0
202	Liver Transplantation in Children: Post-Transplant Care. 2021 , 816-832		1

201	Current Evidence on the Clinical Relevance of Donor-specific Antibodies in Paediatric Liver Transplantation. 2021 , 72, 788-793		0
200	Donor age (≥5 years) and reduced immunosuppression are associated with the recurrent primary sclerosing cholangitis after liver transplantation - a multicenter retrospective study. 2021 , 34, 916-929		0
199	Autoimmune Hepatitis in Children. 2021 , 321-332		
198	Liver Transplant Pathology. 2021 , 393-402		
197	Mitochondrial Consequences of Organ Preservation Techniques during Liver Transplantation. 2021 , 22,		5
196	The efficacy of rituximab treatment for antibody-mediated rejection in liver transplantation: A retrospective Japanese nationwide study. 2021 , 51, 990-999		1
195	Post-transplant Lymphoproliferative Disorders After Liver Transplantation: A Retrospective Cohort Study Including 1954 Transplants. <i>Liver Transplantation</i> , 2021 , 27, 1165-1180	4.5	1
194	Serum MicroRNA Transcriptomics and Acute Rejection or Recurrent Hepatitis C Virus in Human Liver Allograft Recipients: A Pilot Study. <i>Transplantation</i> , 2021 ,	1.8	1
193	HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers. 2021 , 12, 688301		3
192	Neurological complications after living-donor liver transplantation in children. 2021 , 43, 637-643		2
191	Presence of donor specific HLA class 2 antibodies (DSA class 2) is associated with development of graft fibrosis more than 10 years after liver transplantation-a retrospective single center study. 2021 , 35, e14336		1
190	Risk Factors Affecting Outcomes in Pediatric Liver Transplantation: A Real-World Single-Center Experience. 2021 , 26, e929145		0
189	Lactic Acidosis, Hypoglycemia, and Eosinophilia: Novel Markers of Antibody-Mediated Rejection Causing Graft Ischemia. <i>Liver Transplantation</i> , 2021 , 27, 1857-1860	4.5	1
188	Immunosuppression Free Protocol for Liver Transplant from an Identical Twin Mimicking Positive Donor-Specific Antibodies: A Case Report. 2021 , 53, 2576-2579		0
187	Clinical parameters and biomarkers predicting spontaneous operational tolerance after liver transplantation: A scoping review. <i>American Journal of Transplantation</i> , 2021 , 21, 3312-3323	8.7	0
186	HLA-DR Mismatch and Black Race Are Associated With Recurrent Autoimmune Hepatitis After Liver Transplantation. <i>Transplantation Direct</i> , 2021 , 7, e714	2.3	0
185	Acute rejection on immune-mediated chronic rejection after liver transplantation. 2021 , 180,		
184	Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies. 2021 , 14, 2697-2712		0

183	Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation. 2021 , 13, 673-685		0
182	Sinusoidal obstruction syndrome as a manifestation of acute antibody-mediated rejection after liver transplantation. <i>American Journal of Transplantation</i> , 2021 , 21, 3775-3779	8.7	1
181	Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. 2021 , 66, 101386		6
180	Non-invasive diagnosis and follow-up in liver transplantation. 2021 , 46, 101774		0
179	Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. 2021 , 75, 1203-1216		2
178	Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey. <i>Transplantation Direct</i> , 2021 , 7, e729	2.3	1
177	Prediction of Liver Transplant Rejection with a Biologically Relevant Gene Expression Signature. <i>Transplantation</i> , 2021 ,	1.8	3
176	Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study. <i>Transplantation Direct</i> , 2021 , 7, e722	2.3	0
175	The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes. 2021 , 8971900211034261		
174	Allograft Fibrosis After Pediatric Liver Transplantation: Incidence, Risk Factors, and Evolution. <i>Liver Transplantation</i> , 2021 ,	4.5	0
173	Vitamin D Insufficiency Prior to Paediatric Liver Transplantation Is Associated with Early T-Cell Mediated Rejection. 2021 , 8,		1
172	Sensitization and Desensitization in Vascularized Composite Allotransplantation. 2021 , 12, 682180		1
171	ABO Incompatible Liver Transplantation in Children: A 20 Year Experience from Centres in the TransplantChild European Reference Network. 2021 , 8,		0
170	Immunological features and complications in patients with glycogen storage disease 1b after living donor liver transplantation. 2021 , 25, e14104		0
169	Donor HLA Class 1 Evolutionary Divergence Is a Major Predictor of Liver Allograft Rejection : A Retrospective Cohort Study. 2021 , 174, 1385-1394		1
168	Clinicopathologic Characteristics of Late Acute Antibody-mediated Rejection in Pediatric Liver Transplantation. <i>Transplantation</i> , 2021 , 105, 2045-2053	1.8	6
167	The outcomes of thrombotic microangiopathy after liver transplantation: A nationwide survey in Japan. 2021 ,		0
166	Antibody-Mediated Rejection in Adult Liver Transplant Recipients: A Case Series and Literature Review. 2021 ,		

165	Liver Transplantation With Grafts From Super Obese Donors. <i>Transplantation Direct</i> , 2021 , 7, e770	2.3	0
164	Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021 ,	8.7	1
163	Excellent outcome following emergency deceased donor ABO-incompatible liver transplantation using rituximab and antigen specific immunoabsorption. 2021 , 1-10		0
162	Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients. <i>American Journal of Transplantation</i> , 2021 ,	8.7	2
161	Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation. <i>American Journal of Transplantation</i> , 2021 ,	8.7	1
160	Long Term Outcomes of Liver Transplantation For Patients With Autoimmune Hepatitis. 2021 , 53, 2339-2345		
159	The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond. 2021 , 100, 787-798		6
158	Liver Transplantation in Critically Ill Children. 2021 , 143-160		
157	Evaluation of Graft Fibrosis, Inflammation and Donor-specific Antibodies at Protocol Liver Biopsies in Pediatric Liver Transplant Patients: a Single Center Experience. <i>Transplantation</i> , 2021 ,	1.8	2
156	Chronic Antibody-Mediated Liver Rejection: More than Meets the Eye. 2021 , 2, 1-7		
155	Human Herpesvirus 6 Infection in Pediatric Liver Transplantation: Single-Center Study of Incidence, Outcomes, and Management. 2021 , 10, 599-606		0
154	Early Outcomes With the Liver-kidney Safety Net. <i>Transplantation</i> , 2021 , 105, 1261-1272	1.8	5
153	Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. 2017 , 127, 2492-2504		106
152	Comparison of Liver Graft Regeneration Between ABO-Compatible and ABO-Incompatible Living Donor Liver Transplantation: A Propensity Score Matching Analysis. 2018 , 23, 507-519		8
151	Everolimus-based Therapy in Liver Transplant Recipients: Its Efficacy and Safety in a Real Practice. 2018 , 35, 135-142		1
150	Sinusoidal endotheliitis as a histological parameter for diagnosing acute liver allograft rejection. 2017 , 23, 792-799		6
149	High tacrolimus intra-patient variability is associated with graft rejection, and donor-specific antibodies occurrence after liver transplantation. 2018 , 24, 1795-1802		36
148	Rethinking immune hepatitis, an old concept for liver allograft rejection: Relevance of glutathione S-transferase T1 mismatch. 2018 , 24, 3239-3249		6

147	Revisiting the liver's role in transplant alloimmunity. 2019 , 25, 3123-3135	15
146	T-cell allorecognition of donor glutathione S-transferase T1 in plasma cell-rich rejection. 2017 , 9, 1115-1124	3
145	Dengue Virus Infection in Solid Organ Transplant Recipients: A Case Series and Literature Review. 2019 , 101, 1226-1231	3
144	Efficacy of Antithymocyte Globulin Treatment for Severe Centrilobular Injury Following Pediatric Liver Transplant: Clinical Significance of Monitoring Lymphocyte Subset. 2020 , 18, 325-333	2
143	HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations From a Small, Single-Center Cohort. 2019 , 17, 6-17	11
142	Tacrolimus Inpatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. 2021 , 12, 602764	0
141	Regulatory T-Cell Therapy in Liver Transplantation and Chronic Liver Disease. 2021 , 12, 719954	1
140	Liver transplantation alone for common variable immunodeficiency-related liver diseases: A controversial issue?. <i>Journal of Liver Transplantation</i> , 2021 , 4, 100049	
139	Banff consensus recommendations for steatosis assessment in donor livers. <i>Hepatology</i> , 2021 ,	11.2 2
138	Hematological and biochemical characteristics and diagnostic imaging results in acute T cell-mediated rejection after pediatric liver transplantation. 2021 , e14161	
137	Immunosuppression in liver and intestinal transplantation. 2021 , 54-55, 101767	1
136	Towards tolerance in liver transplantation. 2021 , 54-55, 101770	0
135	Multiplex Immunofluorescence for Detection of Spatial Distributions of Infiltrating T Cells Within Different Regions of Hepatic Lobules During Liver Transplantation Rejection. 2021 , 1	1
134	Antibody-Mediated Rejection. 2017 , 206-207	
133	Tolvaptan for Fluid Management in Living Donor Liver Transplant Recipients. 2018 , 23, 25-33	
132	[Protocol for histological examination of liver transplant dysfunction]. 2019 , 81, 71-73	
131	Liver Pathology in Transplantation. 2019 , 277-286	
130	Pathology of Allograft Liver Dysfunction. 2019 , 565-583	

- 129 Long-Term Outcome of Veno-Occlusive Disease After Liver Transplant: A Retrospective Single-Center Experience. **2019**, 17, 214-221 2
- 128 Immune-Mediated Liver Disease in the Transplanted Liver. **2020**, 597-620
- 127 Prevalence and risk factors of T-cell mediated rejection in patients after liver transplantation from deceased donors: a retrospective study over 10 years. **2020**, 66, e4-e10
- 126 Presentation and Outcomes of Autoimmune Hepatitis Type 1 and Type 2 in Children: A Single-center Study. **2021**, 72, 101-107 0
- 125 Assessment of Donor Liver Pathology Predicts Survival After Liver Transplantation: A Retrospective Cohort Study. **2021**, 53, 2963-2963
- 124 Pediatric Liver Disease. **2020**, 453-469
- 123 The Paucity of Interlobular Bile Ducts. **2020**, 261-272 0
- 122 Liver Transplantation for Autoimmune Hepatitis. **2020**, 125-136
- 121 Comparaci3n entre dos esquemas de inmunosupresi3n en pacientes con trasplante hep3tico en un hospital universitario en Medell3n, Colombia. **2020**, 145-156
- 120 Centrizonal hepatocyte dropout in allograft liver biopsies: A clinicopathologic study. **2021**, 0
- 119 Pleuroparenchymal Fibroelastosis Induced by Liver Transplantation?. **2021**,
- 118 Chronic Rejection and Atherosclerosis in Post-Transplant Cardiovascular Mortality: Two Sides of the Same Coin. **2021**,
- 117 Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. **2021**, 10, 0
- 116 Chronic rejection after liver transplantation: Opening the Pandora's box.. **2021**, 27, 7771-7783 1
- 115 Immunosuppression in Liver Transplantation. **2021**,
- 114 Whole liver transplantation in children under 10 kg: How to minimize the high risks of a still challenging procedure.. **2022**, e14222
- 113 Intra-Liver Allograft C3d-Binding Donor-Specific Anti-HLA Antibodies Predict Rejection After Liver Transplantation.. **2022**, 54, 450-450 0
- 112 Quick preparation of ABO-incompatible living donor liver transplantation for acute liver failure. **2021**, e14555 0

111	The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume.. 2022,		1
110	Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment.. 2022, 101, e28509		
109	Recurrent Liver Allograft Injury in Patients With Donor-Derived Malignancy Treated With Immunosuppression Cessation and Retransplantation.. 2022,		0
108	Refractory Acute Antibody Mediated Rejection in Liver Transplant After Desensitization of Preformed Donor Specific Antibody-Validity of Bortezomib and Everolimus: A Case Report.. 2021, 54, 147-147		1
107	Acute liver failure secondary to acute antibody mediated rejection after compatible liver transplant: A case report.. 2022, 14, 287-294		
106	Role of Histopathology in Liver Dysfunction After Transplant. 2022, 319-332		
105	Rejection and Immunosuppression. 2022, 287-318		
104	Not only a small liver - The pathologist's perspective in the pediatric liver transplant setting.. 2022, 114, 89-103		0
103	Liver Transplantation Outcomes From Controlled Circulatory Death Donors: Static cold storage vs in situ normothermic regional perfusion vs ex situ normothermic machine perfusion.. 2022,		2
102	Adaptation of Imaging Mass Cytometry to Explore the Single Cell Alloimmune Landscape of Liver Transplant Rejection.. 2022, 13, 831103		0
101	Autoimmune hepatitis and liver transplantation: Indications, and recurrent and autoimmune hepatitis.. 2022, 12, 59-64		0
100	Mismatch epitope load predicts de novo-DSA-free survival in pediatric liver transplantation.. 2022, e14251		0
99	Impact of Liver Biopsy Size on Histopathologic Evaluation of Liver Allograft Rejection.. 2022,		
98	Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.. 2022,		0
97	Incidence of Acute Rejection and Patient Survival in Combined Heart-Liver Transplantation.. <i>Liver Transplantation,</i> 2022,	4.5	0
96	Donor-recipient HLA-A mismatching is associated with hepatic artery thrombosis, sepsis, graft loss and reduced survival after liver transplantation.. <i>Liver Transplantation,</i> 2022,	4.5	0
95	Effect of the response to preoperative treatment for hepatorenal syndrome on the outcome of recipients of living-donor liver transplantation.. 2022,		1
94	Evaluation of a Gene Expression Biomarker to Identify Operationally Tolerant Liver Transplant Recipients: The LITMUS Trial.. 2021,		0

93 Posttransplant immune-mediated cholangiopathies.. **2022**, 38, 98-103

92 Correlation Between Microvascular Inflammation in Endomyocardial Biopsies and Rejection Transcripts, Donor-specific Antibodies, and Graft Dysfunction in Antibody-mediated Rejection.. *Transplantation*, **2021**, 1.8 0

91 Renal function after liver transplantation: Real-world experience with basiliximab induction and delayed reduced-dose tacrolimus.. **2021**,

90 Elevated fractional donor-derived cell-free DNA during subclinical graft injury after liver transplantation.. *Liver Transplantation*, **2022**, 4.5 1

89 Standardising the histological assessment of late post-transplant biopsies from paediatric liver allograft recipients.. *Liver Transplantation*, **2022**, 4.5 0

88 Image_1.tif. **2019**,

87 Image_2.tif. **2019**,

86 Table_1.docx. **2019**,

85 Data_Sheet_1.PDF. **2018**,

84 Image_1.pdf. **2019**,

83 DataSheet_1.pdf. **2020**,

82 Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis.. **2022**, 35, 10182 0

81 Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy.. **2022**, 12, 7647 0

80 CAQ Corner: Basic Concepts of Transplant Immunology.. *Liver Transplantation*, **2022**, 4.5

79 Non-Invasive Biomarkers for the Diagnosis and Management of Autoimmune Hepatitis. *Hepatology*, 11.2 2

78 The Impact of Human Leukocyte Antigen Mismatch on Recipient Outcomes in Living-Donor Liver Transplantation. *Liver Transplantation*, 4.5 0

77 New Approaches to the Diagnosis of Rejection and Prediction of Tolerance in Liver Transplantation. *Transplantation*, **16**, Publish Ahead of Print, 1.8 0

76 Incidence and risk factors for the development of cytomegalovirus viremia in a steroid sparing liver transplant center. *Transplant Infectious Disease*, 2.7

75	Transplantation Pathology. 2022 , 353-403		
74	Acute Antibody-Mediated Rejection in Liver Transplantation: Impact and Applicability of the Banff Working Group on Liver Allograft Pathology 2016 Criteria. <i>Human Pathology</i> , 2022 ,	3.7	○
73	"Immunosuppressive drugs in liver transplant: An insight.". <i>Journal of Clinical and Experimental Hepatology</i> , 2022 ,	4.1	○
72	CAQ Corner: Immune-Mediated Complications. <i>Liver Transplantation</i> ,	4.5	
71	Belatacept Treatment of Recurrent Late-onset T Cell-mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient. <i>Transplantation Direct</i> , 2022 , 8, e1076	2.3	
70	Plasma cell-rich acute rejection after living donor liver transplantation: unusual or underestimated diagnosis?. <i>Journal of Liver Transplantation</i> , 2022 , 100108		
69	Current Status of Biomarkers and Molecular Diagnostic Tools for Rejection in Liver Transplantation: Light at the end of the Tunnel?. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 ,	4.1	
68	Seventh Day Syndrome Revisited: Early Recognition of the Clinical Syndrome and an Evolving Understanding of Its Etiology. 1,		
67	Mastering core recommendations during HEPAtology ROUNDS in advanced chronic liver disease. <i>Seminars in Liver Disease</i> ,	7.3	
66	Post-Transplant Immunosuppression in Autoimmune Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 ,	4.1	
65	Characteristics of changes in double positive CD4+CD8+ T cells in liver transplantation. <i>International Immunopharmacology</i> , 2022 , 110, 109028	5.8	○
64	Alloimmune versus autoimmune hepatitis following liver transplantation. 2022 , 20, 21-24		1
63	DSA in solid organ transplantation: is it a matter of specificity, amount, or functional characteristics?. Publish Ahead of Print,		○
62	Reply to: Comments on: Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis. 35,		
61	miR-505-5p alleviates acute rejection of liver transplantation by inhibiting Myd88 and inducing M2 polarization of Kupffer cells. 2022 ,		
60	Modelling kidney outcomes based on MELD eras - impact of MELD score in renal endpoints after liver transplantation. 2022 , 23,		
59	Immunosuppression and liver transplantation. 2022 ,		
58	Acute Antibody-mediated Rejection Coexisting With T Cell-mediated Rejection in Pediatric ABO-incompatible Transplantation. 2022 , 8, e1359		○

- 57 Long-term liver allograft fibrosis: A review with emphasis on idiopathic post-transplant hepatitis and chronic antibody mediated rejection. **2022**, 14, 1541-1549
- 56 Comments on: Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis. 35,
- 55 The New Challenge in Pediatric Liver Transplantation: Chronic Antibody-Mediated Rejection. **2022**, 11, 4834 1
- 54 Impact of DSA and immunosuppression minimization on rejection, graft, and patient survival after simultaneous liver/kidney transplantation. 9,
- 53 Revisiting transplant immunology through the lens of single-cell technologies. 0
- 52 HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation. **2022**, 46, 102024 0
- 51 Donor and Recipient Polymorphisms of MAPK Signaling Pathway Genes Influence Post-Transplant Liver Function in Chinese Liver Transplant Patients Taking Tacrolimus. 0
- 50 Biliary Epithelial Senescence in Cellular Rejection Following Live Donor Liver Transplantation. **2022**, 0
- 49 Dysbiosis and Depletion of Fecal Organic Acids Correlate With the Severity of Rejection After Rat Liver Transplantation. 35, 0
- 48 Nodular Regenerative Hyperplasia Is Not a Rare Condition After Liver Transplantation: Incidence, Predictive Factors, and Impact on Survival. Publish Ahead of Print, 0
- 47 Killer Cell Immunoglobulin-like Receptors (KIR) and Human Leucocyte Antigen C (HLA-C) Increase the Risk of Long-Term Chronic Liver Graft Rejection. **2022**, 23, 12155 1
- 46 Immunotherapy and Hepatocellular Carcinoma. 0
- 45 Achieving permanent transplant tolerance via reverse chimeras in orthotopic liver transplantation. 0
- 44 Evaluation of an Abnormal Liver Panel After Liver Transplantation. **2022**, 0
- 43 Immunology of simultaneous liver and kidney transplants with identification and prevention of rejection. 1, 0
- 42 Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?: A systematic review and meta-analysis. 13, 0
- 41 Foxp3+ regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation. 13, 0
- 40 Antineoplastic chemotherapy and immunosuppression in liver transplant recipients: Squaring the circle?. 0

- 39 Diagnosis and classification of vascular liver disorders. **2023**, 29, 36-51 ○
- 38 Risk factors for acute rejection in liver transplantation and its impact on the outcomes of recipients. **2023**, 76, 101767 ○
- 37 Regular protocol liver biopsy is useful to adjust immunosuppressant dose after adult liver transplantation. ○
- 36 The fate of donor-type ABO blood group antigen expression in liver grafts in ABO -incompatible adult living donor liver transplantation. ○
- 35 Impact of High MELD Scores on CMV Viremia Following Liver Transplantation. ○
- 34 Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document. **2023**, 23, 115-132 1
- 33 Incidence and risk factors of subclinical rejection after pediatric liver transplantation, and impact on allograft fibrosis. ○
- 32 Liver transplantation for autoimmune hepatitis: Pre-transplant does not predict the early post-transplant outcome. ○
- 31 Donor and recipient polymorphisms of MAPK signaling pathway genes influence post-transplant liver function in Chinese liver transplant patients taking tacrolimus. **2023**, 857, 147190 ○
- 30 Subset-specific Retention of Donor Myeloid Cells After Major Histocompatibility Complex-matched and Mismatched Liver Transplantation. Publish Ahead of Print, ○
- 29 Acute Antibody-Mediated Rejection in Liver Transplant Recipients with Autoimmune Liver Disease: A Clinical and Pathologic Study of 4 Cases. **2023**, 13, 41 ○
- 28 Transplantation. **2023**, 599-674 ○
- 27 Are protocol graft biopsies after pediatric liver transplantation useful? Experience in a single center over 20 years. **2023**, 37, ○
- 26 T-cell infiltrate intensity is associated with delayed response to treatment in late acute cellular rejection in pediatric liver transplant recipients. ○
- 25 Impact of very early introduction of everolimus on liver regeneration after partial liver transplantation in rats. ○
- 24 Monitoring of Serological, Cellular and Genomic Biomarkers in Transplantation, Computational Prediction Models and Role of Cell-Free DNA in Transplant Outcome. **2023**, 24, 3908 ○
- 23 HERV1-env Induces Unfolded Protein Response Activation in Autoimmune Liver Disease: A Potential Mechanism for Regulatory T Cell Dysfunction. **2023**, 210, 732-744 ○
- 22 Pathology of Liver, Small Bowel, and Pancreas Transplantation. **2024**, 657-689 ○

- 21 ABO-incompatible Pediatric Liver Transplantation With Antibody and B-cell Depletion-free Immunosuppressive Protocol in High Consanguinity Communities. **2022**, 8, e1353 ○
- 20 Pre-existing non-human leukocyte antigen antibodies are associated with allograft rejection after thoracic transplantation. **2023**, 77, 101794 ○
- 19 Risk factors for antibody-mediated rejection in ABO blood-type incompatible and donor-specific antibody-positive liver transplantation. Publish Ahead of Print, ○
- 18 Late-Onset Rejection in Liver Allograft Biopsies: An Analysis of Process, Pattern, and Clinical Implications. **2023**, 159, 283-292 ○
- 17 Concomitant cutaneous graft-versus-host disease and solid organ rejection: an unreported presentation. ○
- 16 Impact of steroid withdrawal on subclinical graft injury after liver transplantation: A propensity score-matched cohort analysis. 2, ○
- 15 Long-term outcome of liver transplantation for autoimmune hepatitis: A French nationwide study over 30 years. ○
- 14 Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant. **2023**, 6, e230819 ○
- 13 The role of immunosuppression in long-term graft hepatitis and fibrosis after paediatric liver transplant: A comparison of two treatment protocols. 1, ○
- 12 Pediatric Liver Transplantation. **2023**, 415-427 ○
- 11 Correlation of Luminex-Based Single Antigen Based Results With Complement-Dependent Cytotoxicity Crossmatch and Flow Cytometry Crossmatch Results: A Single-Center Experience From Istanbul. **2023**, ○
- 10 Histologic and Clinical Outcomes of Patients Developing Post-Liver Transplant Plasma Cell-Rich Rejection. ○
- 9 Intensivtherapie im Rahmen der Transplantation solider Organe. **2023**, 1-40 ○
- 8 Banff 2016 Global Assessment and Quantitative Scoring for T Cell-Mediated Liver Transplant Rejection are Interchangeable. **2023**, 2023, 1-7 ○
- 7 Acute rejection after liver transplantation with machine perfusion versus static cold storage: a systematic review and meta-analysis. Publish Ahead of Print, ○
- 6 Transplantation Pathology. **2024**, 947-1038 ○
- 5 Bile Duct Diseases. **2024**, 556-643 ○
- 4 Autoimmune Hepatitis. **2024**, 527-555 ○

- 3 Quantification of extracellular matrix remodeling for the non-invasive identification of graft fibrosis after liver transplantation. **2023**, 13,
- 2 Morphological aspects of small-duct cholangiopathies: A minireview. 15, 538-553
- 1 Combination of everolimus and low-dose tacrolimus controls histological liver allograft injury as sufficiently as high-dose tacrolimus. 2,